5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | NEUTRAL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 10.91▼ | 10.91▼ | 10.91▼ | 10.76▲ | 10.79▼ |
MA10 | 10.91▼ | 10.91▼ | 10.91▼ | 10.74▲ | 10.80▼ |
MA20 | 10.86▼ | 10.85▼ | 10.83▼ | 10.82▼ | 10.52▲ |
MA50 | 10.49▲ | 10.48▲ | 10.44▲ | 10.81▼ | 10.32▲ |
MA100 | 10.33▲ | 10.32▲ | 10.31▲ | 10.49▲ | 10.39▲ |
MA200 | 10.32▲ | 10.35▲ | 10.46▲ | 10.32▲ | 13.27▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.027▼ | -0.028▼ | -0.027▼ | -0.008▼ | 0.002▲ |
RSI | 50.082▲ | 50.550▲ | 50.981▲ | 48.829▼ | 54.154▲ |
STOCH | 53.925 | 53.925 | 53.925 | 52.317 | 27.408 |
WILL %R | -86.275▼ | -86.275▼ | -86.275▼ | -65.217 | -69.159 |
CCI | -68.263 | -80.744 | -80.744 | -0.933 | -36.179 |
Thursday, August 14, 2025 05:16 AM
Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call.
|
Wednesday, August 13, 2025 08:37 AM
Discover DiaMedica Therapeutics' Q2 2025 earnings call highlights: promising preeclampsia trial results, progress in stroke programs & a $60M extended ...
|
Wednesday, August 06, 2025 05:19 AM
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 10.745 | 10.77 | 10.72 | 10.76 | 1,800 |
14/08/25 | 10.63 | 10.69 | 10.60 | 10.69 | 1,202 |
13/08/25 | 10.74 | 10.865 | 10.74 | 10.865 | 1,400 |
12/08/25 | 10.765 | 10.765 | 10.72 | 10.735 | 1,100 |
11/08/25 | 10.74 | 10.78 | 10.63 | 10.73 | 2,300 |
08/08/25 | 10.6706 | 10.6985 | 10.65 | 10.6985 | 2,125 |
07/08/25 | 10.71 | 10.71 | 10.65 | 10.661 | 4,200 |
06/08/25 | 10.792 | 10.82 | 10.7496 | 10.7496 | 4,142 |
05/08/25 | 10.779 | 10.779 | 10.779 | 10.779 | 400 |
04/08/25 | 10.65 | 10.80 | 10.60 | 10.78 | 2,500 |
|
|
||||
|
|
||||
|
|